Zoek in de HOVON website
Netwerk Moleculaire Diagnostiek
In hemato-oncology, molecular diagnostics is important for adequate patient stratification into different risk categories. At diagnosis, the choice of treatment ofeten depends on the presence or absence of a genetic defect. During treatment and follow-up, monitoring of minimal residual disease using molecular methods provides a sensitive way to determine response to (novel) therapy and to follow the subsequent course of the diseases at sub-clinical levels.
To this end a network was initiated by several Dutch and Belgian hematological centers in 1996 (MODHEM Network for Molecular Diagnostics of Hematologic Malignancies). The main objectives of the network are the free exchange of materials and methods, standardization of techniques in terms of sensitivity and specificity, the organization of quality control round, and implementation of new developments.
The MODHEM organizes quality control rounds with blinded samples to achieve standardization and high quality among the participating molecular diagnostic laboratories. Blinded samples are send 5 times a year, each time covering a particular subset of hematological malignancies, e.g., AML (AML1-ETO, CBFB-MYH11, FLT3 mutations, NPM1 mutations, CEBPA mutations and EVI1 overexpression), APL (PML-RARA) , CML (BCR-ABL), MPD (JAK2 V617F mutations) or ALL (BCR-ABL and MLL-AF4) or patient/donor samples to determine chimerism.
The results of the quality control rounds are presented and discussed at bi-annual meetings with all members of the MODHEM.
MODHEM has joined the SKML in 2012.
Further information is available at: www.modhem.nl